Neumirna Therapeutics, a Copenhagen, Denmark-based RNA-focused biotech company, raised €20M in Series A funding.
The round was led by Angelini Ventures and Invivo Partners with participation from Innovestor’s Life Science Fund and other existing investors.
The company intends to use the funds to support clinical development of its lead asset NMT.001, a potential disease-modifying Antisense Oligonucleotide (ASO) therapy for drug-resistant epilepsy, as well as expand its R&D capabilities and scale its pioneering drug discovery platform.
Founded in 2020 by Dr. Henrik Klitgaard, Prof. Sakari Kauppinen and Lars Hellerung Christiansen, and led by CEO Professor Janine Erler, Neumirna is a biotechnology company focused on developing RNA-based therapies providing a drug development platform that enables the development of RNA therapies targeting previously intractable conditions, such as drug-resistant epilepsy (DRE) and Parkinson’s disease.
FinSMEs
08/01/2025